1-7 of 7
Ronald Herbst
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR

Shenlan Mao, Raghothama Chaerkady, Wen Yu, Gina D’Angelo, Andrew Garcia, Hong Chen, Allison M. Barrett, Sandrina Phipps, Ryan Fleming, Sonja Hess, Jens-Oliver Koopmann, Nazzareno Dimasi, Susan Wilson, Kathryn Pugh, Kimberly Cook, Luke A. Masterson, Changshou Gao, Herren Wu, Ronald Herbst, Philip W. Howard, David A. Tice, Mark Cobbold, Jay Harper
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2021) 20 (3): 541–552.
https://doi.org/10.1158/1535-7163.MCT-20-0351
Published: 02 March 2021
View article titled, Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR
Open the PDF for Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR in another window
Includes: Supplementary data
Journal Articles

Improved Therapeutic Window in BRCA-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition

Haihong Zhong, Cui Chen, Ravinder Tammali, Shannon Breen, Jing Zhang, Christine Fazenbaker, Maureen Kennedy, James Conway, Brandon W. Higgs, Nicholas Holoweckyj, Rajiv Raja, Jay Harper, Andrew J. Pierce, Ronald Herbst, David A. Tice
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2019) 18 (1): 89–99.
https://doi.org/10.1158/1535-7163.MCT-18-0314
Published: 02 January 2019
View article titled, Improved Therapeutic Window in <em>BRCA</em>-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition
Open the PDF for Improved Therapeutic Window in <em>BRCA</em>-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition in another window
Includes: Supplementary data
Journal Articles

Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer

Song Cho, Francesca Zammarchi, David G. Williams, Carin E.G. Havenith, Noel R. Monks, Peter Tyrer, Francois D'Hooge, Ryan Fleming, Kapil Vashisht, Nazzareno Dimasi, Francois Bertelli, Simon Corbett, Lauren Adams, Halla W. Reinert, Sandamali Dissanayake, Charles E. Britten, Wanda King, Karma Dacosta, Ravinder Tammali, Kevin Schifferli, Patrick Strout, Martin Korade, III, Mary Jane Masson Hinrichs, Simon Chivers, Eva Corey, He Liu, Sae Kim, Neil H. Bander, Philip W. Howard, John A. Hartley, Steve Coats, David A. Tice, Ronald Herbst, Patrick H. van Berkel
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2018) 17 (10): 2176–2186.
https://doi.org/10.1158/1535-7163.MCT-17-0982
Published: 01 October 2018
View article titled, Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer
Open the PDF for Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A138: Loss of the lysosomal transporter SLC46A3 is a mechanism for innate and acquired resistance to non-cleavable maytansine and pyrrolobenzodiazepine-based antibody-drug conjugates

Krista Kinneer, John Meekin, Sandrina Phipps, Binyam Bezabeh, Ryan Fleming, Christine Kiefer, Marlon Rebelatto, Nazzareno Dimasi, Michael J. Wick, Alyssa Moriarty, Megan Groves, Ronald Herbst, Arnaud Tiberghien, Luke Masterson, Philip Howard, David Tice
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A138.
https://doi.org/10.1158/1535-7163.TARG-17-A138
Published: 01 January 2018
View article titled, Abstract A138: Loss of the lysosomal transporter SLC46A3 is a mechanism for innate and acquired resistance to non-cleavable maytansine and pyrrolobenzodiazepine-based antibody-drug conjugates
Journal Articles

Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody–Drug Conjugate Targeting 5T4

Jay Harper, Christopher Lloyd, Nazzareno Dimasi, Dorin Toader, Rose Marwood, Leeanne Lewis, David Bannister, Jelena Jovanovic, Ryan Fleming, Francois D'Hooge, Shenlan Mao, Allison M. Marrero, Martin Korade, III, Patrick Strout, Linda Xu, Cui Chen, Leslie Wetzel, Shannon Breen, Lilian van Vlerken-Ysla, Sanjoo Jalla, Marlon Rebelatto, Haihong Zhong, Elaine M. Hurt, Mary Jane Hinrichs, Keven Huang, Philip W. Howard, David A. Tice, Robert E. Hollingsworth, Ronald Herbst, Adeela Kamal
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (8): 1576–1587.
https://doi.org/10.1158/1535-7163.MCT-16-0825
Published: 02 August 2017
View article titled, Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody–Drug Conjugate Targeting 5T4
Open the PDF for Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody–Drug Conjugate Targeting 5T4 in another window
Includes: Supplementary data
Journal Articles

A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response

Zhan Xiao, Rosa A. Carrasco, Kevin Schifferli, Krista Kinneer, Ravinder Tammali, Hong Chen, Ray Rothstein, Leslie Wetzel, Chunning Yang, Partha Chowdhury, Ping Tsui, Philipp Steiner, Bahija Jallal, Ronald Herbst, Robert E. Hollingsworth, David A. Tice
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (4): 689–701.
https://doi.org/10.1158/1535-7163.MCT-15-0555
Published: 05 April 2016
View article titled, A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of <em>PTEN</em> Status on Tumor Response
Open the PDF for A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of <em>PTEN</em> Status on Tumor Response in another window
Includes: Supplementary data
Journal Articles

Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint

Gregory M. Chin, Ronald Herbst
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2006) 5 (10): 2580–2591.
https://doi.org/10.1158/1535-7163.MCT-06-0201
Published: 13 October 2006
View article titled, Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint
Open the PDF for Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint in another window
Includes: Multimedia, Supplementary data